EQUITY RESEARCH MEMO

Basilard BioTech

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)60/100

Basilard BioTech is a Southern-California-based company pioneering a disruptive gene delivery platform called Celletto™, which uses nanomechanical force to deliver genetic material into cells. Founded in 2018, the company aims to revolutionize cell and gene therapy (CGT) by overcoming the limitations of viral and lipid-based delivery methods. Celletto™ enhances transfection efficiency, reduces toxicity, and enables delivery to hard-to-transfect cell types, including primary and stem cells. The platform is designed for both ex vivo and in vivo applications, positioning Basilard as a key enabler in the rapidly growing CGT market. The company is currently in the preclinical stage, with a focus on developing its own pipeline of engineered cell therapies and licensing the technology to partners.

Upcoming Catalysts (preview)

Q4 2026IND Filing for Lead Program65% success
Q4 2026Series B Financing70% success
Q2 2027Major Pharma Partnership50% success

Locked sections

· Pipeline Analysis
· Competitive Landscape
· Catalyst Calendar (full 12-month)
· Bull Case
· Bear Case
· Counterfactual Scenarios
· Valuation Notes
· SEC Filing Highlights
· Insider Activity
· Literature Watch
· Patent Landscape
· Mechanism Cluster Map
· Audio Briefing (5 min)